{"id":"fasudil","rwe":[{"pmid":"41889986","year":"2026","title":"Anti-inflammatory and pro-proliferative effects of fasudil in human trisomy 21 neural progenitor cells.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"41874470","year":"2026","title":"Molecular Interplay of Small Molecules and Calcium Ions with α-Synuclein Revealed by NMR and Molecular Dynamics Simulations.","finding":"","journal":"ACS chemical neuroscience","studyType":"Clinical Study"},{"pmid":"41866641","year":"2026","title":"The beneficial effects of clazosentan on the perioperative management of patients with subarachnoid hemorrhage.","finding":"","journal":"Neurosurgical review","studyType":"Clinical Study"},{"pmid":"41860032","year":"2026","title":"[Expression of Concern] Fasudil, a Rho‑associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats.","finding":"","journal":"International journal of molecular medicine","studyType":"Clinical Study"},{"pmid":"41814801","year":"2026","title":"[Mechanism of Shenmai Injection in inducing immediate hypersensitivity by activating RhoA/ROCK signaling pathway].","finding":"","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","studyType":"Clinical Study"}],"tags":[{"label":"fasudil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Rho-associated protein kinase 2","category":"target"},{"label":"ROCK2","category":"gene"},{"label":"ROCK1","category":"gene"},{"label":"PKN3","category":"gene"},{"label":"C04AX32","category":"atc"},{"label":"Active","category":"status"},{"label":"Cerebral ischemia","category":"indication"},{"label":"Spasm of cerebral arteries","category":"indication"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Protein Kinase Inhibitors","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FASUDIL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:05:48.738822+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:05:53.820056+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FASUDIL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:05:54.165634+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL541388/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:05:54.961145+00:00"}},"allNames":["fasudil HCl semihydrate","fasudil hydrochloride","fasudil","HA-1077","fasudil hydrochloride hydrate","HA1077","fasudil HCl"],"offLabel":[],"synonyms":["fasudil HCl semihydrate","fasudil hydrochloride","fasudil","HA-1077","fasudil hydrochloride hydrate","HA1077","fasudil HCl"],"timeline":[{"date":"1995-06-30","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"approvals":[{"date":"1995-06-30","orphan":false,"company":"","regulator":"PMDA"}],"ecosystem":[{"indication":"Cerebral ischemia","otherDrugs":[{"name":"papaverine","slug":"papaverine","company":""},{"name":"pentobarbital","slug":"pentobarbital","company":"Oak Pharms"},{"name":"phentolamine","slug":"phentolamine","company":"Novartis"}],"globalPrevalence":null},{"indication":"Spasm of cerebral arteries","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Rho-associated protein kinase 2","targets":[{"gene":"ROCK2","source":"DrugCentral","target":"Rho-associated protein kinase 2","protein":"Rho-associated protein kinase 2"},{"gene":"ROCK1","source":"DrugCentral","target":"Rho-associated protein kinase 1","protein":"Rho-associated protein kinase 1"},{"gene":"PKN3","source":"DrugCentral","target":"Serine/threonine-protein kinase N3","protein":"Serine/threonine-protein kinase N3"},{"gene":"CLK1","source":"DrugCentral","target":"Dual specificity protein kinase CLK1","protein":"Dual specificity protein kinase CLK1"},{"gene":"PKN2","source":"DrugCentral","target":"Serine/threonine-protein kinase N2","protein":"Serine/threonine-protein kinase N2"},{"gene":"PRKACA","source":"DrugCentral","target":"cAMP-dependent protein kinase catalytic subunit alpha","protein":"cAMP-dependent protein kinase catalytic subunit alpha"},{"gene":"PKN1","source":"DrugCentral","target":"Serine/threonine-protein kinase N1","protein":"Serine/threonine-protein kinase N1"},{"gene":"MELK","source":"DrugCentral","target":"Maternal embryonic leucine zipper kinase","protein":"Maternal embryonic leucine zipper kinase"},{"gene":"NQO2","source":"DrugCentral","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]"},{"gene":"PRKCE","source":"DrugCentral","target":"Protein kinase C epsilon type","protein":"Protein kinase C epsilon type"}],"modality":"Small Molecule","drugClass":"fasudil","explanation":"","oneSentence":"","technicalDetail":"Fasudil acts as a selective inhibitor of ROCK2, preventing the phosphorylation and activation of myosin light chain and subsequent contraction of smooth muscle cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1132","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FASUDIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FASUDIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:13:17.034402","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:05:56.603536+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"phenoxybenzamine","drugSlug":"phenoxybenzamine","fdaApproval":"1953-01-26","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"fasudil","indications":{"approved":[{"name":"Cerebral ischemia","source":"DrugCentral","snomedId":287731003,"regulator":"FDA"},{"name":"Spasm of cerebral arteries","source":"DrugCentral","snomedId":73173006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phenoxybenzamine","brandName":"phenoxybenzamine","genericName":"phenoxybenzamine","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05931575","phase":"PHASE2","title":"Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2023-09-11","conditions":["Idiopathic Parkinson´s Disease"],"enrollment":75,"completionDate":"2026-09-30"},{"nctId":"NCT07250542","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"baotai Liang","startDate":"2024-07-05","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2026-12-30"},{"nctId":"NCT06861192","phase":"PHASE2,PHASE3","title":"Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer","status":"RECRUITING","sponsor":"baotai Liang","startDate":"2025-02-16","conditions":["Prostate CA"],"enrollment":83,"completionDate":"2027-03-16"},{"nctId":"NCT05218668","phase":"PHASE2","title":"Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Woolsey Pharmaceuticals","startDate":"2021-12-22","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":40,"completionDate":"2029-01"},{"nctId":"NCT06890858","phase":"PHASE2","title":"A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-04","conditions":["Ovarian Cancer"],"enrollment":20,"completionDate":"2028-01"},{"nctId":"NCT06362707","phase":"PHASE2","title":"Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)","status":"RECRUITING","sponsor":"Helse Stavanger HF","startDate":"2024-08-01","conditions":["Cognitive Decline, Mild","Alzheimer Disease"],"enrollment":200,"completionDate":"2026-10-01"},{"nctId":"NCT03792490","phase":"PHASE2","title":"Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS","status":"COMPLETED","sponsor":"University Medical Center Goettingen","startDate":"2019-02-20","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":120,"completionDate":"2023-11-01"},{"nctId":"NCT04793659","phase":"PHASE2","title":"Fasudil fOr redUcing elopemeNt and Spatial Disorientation","status":"COMPLETED","sponsor":"Woolsey Pharmaceuticals","startDate":"2020-12-15","conditions":["Dementia"],"enrollment":24,"completionDate":"2022-02-11"},{"nctId":"NCT04734379","phase":"PHASE2","title":"Rho Kinase (ROCK) Inhibitor in Tauopathies - 1","status":"UNKNOWN","sponsor":"Woolsey Pharmaceuticals","startDate":"2021-01-22","conditions":["Progressive Supranuclear Palsy","Corticobasal Syndrome"],"enrollment":15,"completionDate":"2023-11-30"},{"nctId":"NCT03404843","phase":"PHASE2","title":"Red Blood Cell ATP Release and Vascular Function in Humans","status":"COMPLETED","sponsor":"Colorado State University","startDate":"2017-07-14","conditions":["Cardiovascular Diseases"],"enrollment":31,"completionDate":"2018-10-05"},{"nctId":"NCT04191954","phase":"PHASE2,PHASE3","title":"Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2019-06-02","conditions":["Retinopathy of Prematurity"],"enrollment":184,"completionDate":"2020-09"},{"nctId":"NCT03753269","phase":"PHASE4","title":"Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-07-01","conditions":["ST Segment Elevation Myocardial Infarction"],"enrollment":600,"completionDate":"2022-12-30"},{"nctId":"NCT03391219","phase":"PHASE2,PHASE3","title":"Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2018-01","conditions":["Retinal Vein Occlusion"],"enrollment":36,"completionDate":"2018-10"},{"nctId":"NCT01823081","phase":"PHASE3","title":"Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2013-01","conditions":["Diabetic Macular Edema"],"enrollment":74,"completionDate":"2015-12"},{"nctId":"NCT00670202","phase":"PHASE2","title":"Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-03-13","conditions":["Carotid Stenosis"],"enrollment":2,"completionDate":"2011-01-20"},{"nctId":"NCT00498615","phase":"PHASE3","title":"A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-04","conditions":["Raynaud","Scleroderma"],"enrollment":17,"completionDate":"2012-03"},{"nctId":"NCT01935518","phase":"PHASE2","title":"A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2013-09","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":10,"completionDate":"2015-05"},{"nctId":"NCT00120718","phase":"PHASE2","title":"The Effect of Fasudil on Vascular Function in Humans","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2002-06","conditions":["Atherosclerosis","Hypercholesterolemia"],"enrollment":60,"completionDate":"2007-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"Q0CH43PGXS","CHEBI":"CHEBI:43871","INN_ID":"6696","UMLSCUI":"C0062068","chemblId":"CHEMBL541388","ChEMBL_ID":"CHEMBL541388","KEGG_DRUG":"D01840","DRUGBANK_ID":"DB08162","PDB_CHEM_ID":" M77","PUBCHEM_CID":"3547","IUPHAR_LIGAND_ID":"5181","SECONDARY_CAS_RN":"105628-07-7","MESH_SUPPLEMENTAL_RECORD_UI":"C049347"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.44 hours","clearance":"77.5 mL/min/kg","volumeOfDistribution":"1.22 L/kg"},"publicationCount":1483,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"C04AX32","allCodes":["C04AX32"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 20","pmid":"41889986","title":"Anti-inflammatory and pro-proliferative effects of fasudil in human trisomy 21 neural progenitor cells.","journal":"bioRxiv : the preprint server for biology"},{"date":"2026 Mar 24","pmid":"41874470","title":"Molecular Interplay of Small Molecules and Calcium Ions with α-Synuclein Revealed by NMR and Molecular Dynamics Simulations.","journal":"ACS chemical neuroscience"},{"date":"2026 Mar 23","pmid":"41866641","title":"The beneficial effects of clazosentan on the perioperative management of patients with subarachnoid hemorrhage.","journal":"Neurosurgical review"},{"date":"2026 May","pmid":"41860032","title":"[Expression of Concern] Fasudil, a Rho‑associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats.","journal":"International journal of molecular medicine"},{"date":"2026 Feb","pmid":"41814801","title":"[Mechanism of Shenmai Injection in inducing immediate hypersensitivity by activating RhoA/ROCK signaling pathway].","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"FASUDIL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"1995-06-30T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:05:56.603536+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}